Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PK/PD Clear all
Completed Phase 1Phase 2 Interventional Results available

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

NCT06056570
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD

NCT01872572
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Subcutaneous RB006 0.5 mg/kg, Subcutaneous RB006 1.0 mg/kg, Subcutaneous RB006 3.0 mg/kg, Subcutaneous RB006 2.0 mg, Placebo
Drug
Lead sponsor
Regado Biosciences, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

NCT01095510
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CINRYZE
Biological
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

NCT03870555
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-954, TAK-954 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Early Phase 1 Interventional

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

NCT06109948
View directory record Official record
Conditions
Healthy, Late Onset Pompe Disease
Interventions
ABX1100 injection for IV infusion, Placebo injection for IV infusion
Drug
Lead sponsor
Aro Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Orange, California • St Louis, Missouri • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

NCT04074317
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Interventions
PRAM9, Regular Insulin + Pramlintide, Regular Insulin
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

NCT00419666
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Calcitriol 3mcg/g
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • San Diego, California • Eagan, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

NCT06086522
View directory record Official record
Conditions
Solid Tumor
Interventions
QN-302
Drug
Lead sponsor
Qualigen Theraputics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

NCT07350577
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
ALTB-268, Placebo
Biological · Other
Lead sponsor
AltruBio Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

NCT05378672
View directory record Official record
Conditions
Hypoglycemia, Type 1 Diabetes
Interventions
Dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
Up to 5 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023
View directory record Official record
Conditions
Schizophrenia
Interventions
D-serine
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
New Haven, Connecticut • Glen Oaks, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and PD Study of Oral F/TAF for HIV Prevention

NCT02904369
View directory record Official record
Conditions
HIV
Interventions
Emtricitabine, Tenofovir alafenamide, Tenofovir disoproxil
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Jul 24, 2026, 4:14 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

NCT04082481
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-988, TAK-988 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Glendale, California • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

NCT01335009
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MORAb-004 (monoclonal antibody)
Biological
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT05539872
View directory record Official record
Conditions
Pharmacokinetics, Pharmacodynamics
Interventions
I004, NovoLog
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Results available

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

NCT02819726
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAIT101, MabThera, Rituxan
Biological
Lead sponsor
Archigen Biotech Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678
View directory record Official record
Conditions
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of ATX-01 in Participants With DM1

NCT06300307
View directory record Official record
Conditions
Myotonic Dystrophy 1
Interventions
ATX-01, Placebo
Drug
Lead sponsor
ARTHEx Biotech S.L.
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Jul 24, 2026, 4:14 AM EDT
Recruiting Phase 4 Interventional

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

NCT00340704
View directory record Official record
Conditions
Bladder, Neurogenic
Interventions
tamsulosin hydrochloride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 16 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jul 24, 2026, 4:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM

NCT03646721
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DA-1241, Placebo, Sitagliptin
Drug
Lead sponsor
Dong-A ST Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jul 24, 2026, 4:14 AM EDT